This is a standard preclinical milestone for a micro-cap biotech. No immediate catalyst — monitor for GLP-tox study initiation and eventual IND filing as the next meaningful events.
Price Chart
Executive Summary
MIRA Pharmaceuticals announced positive results from 7-day dose-range finding toxicology and toxicokinetic studies of MIRA-55, its oral non-opioid candidate for inflammatory pain, in rats and dogs. The data support dose selection for the next phase of IND-enabling studies, with an IND submission targeted for Q1 2027. This is a routine preclinical milestone for a clinical-stage biotech with a $32M market cap, providing no new financial data or fundamental change in the company's outlook.
Key Facts
- Positive 7-day dose-range finding toxicology and toxicokinetic studies completed for MIRA-55 in rats and dogs.
- Rats identified as the more sensitive species; dogs demonstrated greater tolerance.
- Results inform dose selection for next phase of IND-enabling program.
- Company targets IND submission to FDA in Q1 2027, subject to successful completion of remaining studies.
- MIRA-55 is an investigational oral, non-opioid drug candidate for inflammatory pain.
- DEA has determined MIRA-55 is not classified as a controlled substance.
- Global non-opioid pain-treatment market projected to reach ~$70.3 billion by 2030 (7.7% CAGR).
Financial Impact
No financial data reported. Filing is a preclinical development update with no revenue, earnings, or guidance impact.
Risk Factors
- Preclinical results may not translate to human clinical trials.
- Remaining IND-enabling studies may fail or be delayed.
- Company has a $32M market cap and may require additional financing to fund development.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-040930 |
| Exhibit: ex99-1.htm | 0001493152-26-040930 |
| Document: 0001493152-26-040930-index-headers.html | 0001493152-26-040930 |
| Document: 0001493152-26-040930-index.html | 0001493152-26-040930 |
| Document: 0001493152-26-040930.txt | 0001493152-26-040930 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $0.6290 $0.6195 | ▼ −1.51% | ▼ −0.99% | $0.5597 (−11.02%) |
Oct 22, 2026 5d ago | Press Release | $0.6289 $0.6195 | ▼ −1.49% | ▼ −0.97% | $0.5597 (−11.00%) |
Sep 17, 2026 5w ago | 8-K | $0.7593 $0.8323 | ▲ +9.61% | ▲ +9.73% | $0.5597 (−26.29%) |
Sep 17, 2026 5w ago | Press Release | $0.7593 $0.8323 | ▲ +9.61% | ▲ +9.73% | $0.5597 (−26.29%) |
Sep 1, 2026 8w ago | 8-K | $0.8600 $0.8495 | ▼ −1.22% | ▼ −1.66% | $0.5597 (−34.92%) |
Aug 6, 2026 11w ago | 8-K | $0.6782 $0.7400 | ▲ +9.11% | ▲ +8.50% | $0.5597 (−17.47%) |
Jul 10, 2026 15w ago | 8-K | $0.9245 $0.9097 | ▼ −1.60% | ▼ −0.84% | $0.5597 (−39.46%) |
Jul 6, 2026 16w ago | 8-K | $0.9549 $0.9478 | ▼ −0.74% | ▼ −0.27% | $0.5597 (−41.39%) |
Jun 17, 2026 18w ago | 8-K | $0.9782 $0.9524 | ▼ −2.64% | ▼ −3.42% | $0.5597 (−42.78%) |
Jun 8, 2026 20w ago | 8-K | $0.9767 $0.9802 | ▲ +0.36% | ▲ +1.93% | $0.5597 (−42.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers